L
603669
vs
S
Shanghai Composite
Over the past 12 months, Lionco Pharmaceutical Group Co Ltd has underperformed Shanghai Composite, delivering a return of -33% compared to the Shanghai Composite's +15% growth.
Stocks Performance
603669 vs Shanghai Composite
Performance Gap
603669 vs Shanghai Composite
Performance By Year
603669 vs Shanghai Composite
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Lionco Pharmaceutical Group Co Ltd
Glance View
Lionco Pharmaceutical Group Co., Ltd. engages in the sale of chemical drug and antibiotic agents. The company is headquartered in Shannan, Xizang and currently employs 678 full-time employees. The company went IPO on 2015-05-28. is a China-based company principally engaged in the research and development, production and sales of chemical prescription medicine. The firm's products are mainly categorized in to three areas: parenteral nutrition agents, anti-infectious agents and digestive system agents. The lead product of its parenteral nutrition agents is Glutamine for injection; its anti-infectious agents include Cefodizime sodium for injection and Cefathiamidine for injection, among others; its digestive system agents include Omeprazole Sodium for injection and others. The firm operates its business in domestic market.